Astek Diagnostics
Year2024
RoundSeed
Amount$2M
Overall
Summary
21 slides
21 slides
1 slide
Presenting Astek, dedicated to saving lives through precision diagnostics in antibiotic sensitivity.
1 slide
Our proactive delivery roadmap is set with pivotal timelines leading to FDA approval by 2025.
1 slide
Astek aims for the Jiddu system to revolutionize diagnostics across various sample types.
2 slides
The comprehensive Jiddu system offers a robust approach to diagnosing infections and antibiotic sensitivity with a proven 97% accuracy in urine-based tests.
2 slides
UTIs pose significant health and economic burdens due to outdated diagnostics and improper antibiotic prescriptions, exacerbating antimicrobial resistance.
1 slide
The Jiddu system delivers rapid, accurate UTI detection and antibiotic sensitivity results within an hour, improving patient care and reducing costs.
3 slides
Our technology is designed for ease of use, capturing bacteria efficiently and providing reliable results by measuring metabolic activity and antibiotic efficiency.
2 slides
Astek is propelled by a skilled core team and esteemed advisory board, bringing extensive industry experience and expertise.
2 slides
The Jiddu system has demonstrated high accuracy in pilots; we have strong partnerships and significant funding from investors and grants.
1 slide
Our technology is well-protected with issued and pending patents covering key innovations in diagnostics and sample processing.
1 slide
Our timeline outlines critical milestones from initial pilots to clinical trials and market launch.
1 slide
We seek $XX million via convertible notes to achieve our next phase targets, with compelling terms for investors including tax incentives.
1 slide
Our commercialization strategy focuses on outsourcing production while planning an exit through potential acquisition upon FDA clearance.
1 slide
Comparable successful transactions in the diagnostics market illustrate Astek's potential for high market valuation and acquisition interest.
1 slide
We have built and validated a highly accurate platform and are now pursuing $XXM to complete development and clinical trials.
